Literature DB >> 21717224

Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Linn Moore1, Dong Fan, Ratnadeep Basu, Vijay Kandalam, Zamaneh Kassiri.   

Abstract

Remodeling of the myocardium and the extracellular matrix (ECM) occurs in heart failure irrespective of its initial cause. The ECM serves as a scaffold to provide structural support as well as housing a number of cytokines and growth factors. Hence, disruption of the ECM will result in structural instability as well as activation of a number of signaling pathways that could lead to fibrosis, hypertrophy, and apoptosis. The ECM is a dynamic entity that undergoes constant turnover, and the integrity of its network structure is maintained by a balance in the function of matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitor of metalloproteinases (TIMPs). In heart disease, levels of MMPs and TIMPs are altered resulting in an imbalance between these two families of proteins. In this review, we will discuss the structure, function, and regulation of TIMPs, their MMP-independent functions, and their role in heart failure. We will review the knowledge that we have gained from clinical studies and animal models on the contribution of TIMPs in the development and progression of heart disease. We will further discuss how ECM molecules and regulatory genes can be used as biomarkers of disease in heart failure patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21717224     DOI: 10.1007/s10741-011-9266-y

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  144 in total

1.  Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4).

Authors:  Y E Liu; M Wang; J Greene; J Su; S Ullrich; H Li; S Sheng; P Alexander; Q A Sang; Y E Shi
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

2.  Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling.

Authors:  Ravi Ramani; Kathleen Nilles; Gregory Gibson; Benjamin Burkhead; Michael Mathier; Dennis McNamara; Charles F McTiernan
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

3.  Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.

Authors:  Hideo Izawa; Toyoaki Murohara; Kohzo Nagata; Satoshi Isobe; Hiroyuki Asano; Tetsuya Amano; Sahoko Ichihara; Tomoko Kato; Satoru Ohshima; Yosuke Murase; Shigeo Iino; Koji Obata; Akiko Noda; Kenji Okumura; Mitsuhiro Yokota
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

4.  Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1).

Authors:  M P Vincenti; C I Coon; J A Mengshol; S Yocum; P Mitchell; C E Brinckerhoff
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

5.  FOXO1A differentially regulates genes of decidualization.

Authors:  Oscar L Buzzio; Zhenxiao Lu; Curt D Miller; Terry G Unterman; J Julie Kim
Journal:  Endocrinology       Date:  2006-05-11       Impact factor: 4.736

6.  Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution.

Authors:  A Tuuttila; E Morgunova; U Bergmann; Y Lindqvist; K Maskos; C Fernandez-Catalan; W Bode; K Tryggvason; G Schneider
Journal:  J Mol Biol       Date:  1998-12-11       Impact factor: 5.469

7.  Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.

Authors:  D Kelly; S Khan; G Cockerill; L L Ng; M Thompson; N J Samani; I B Squire
Journal:  Eur J Heart Fail       Date:  2008-01-30       Impact factor: 15.534

8.  TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction.

Authors:  Hai Tian; Massimo Cimini; Paul W M Fedak; Svetlana Altamentova; Shafie Fazel; Ming-Li Huang; Richard D Weisel; Ren-Ke Li
Journal:  J Mol Cell Cardiol       Date:  2007-09-14       Impact factor: 5.000

Review 9.  Macrophage roles following myocardial infarction.

Authors:  Jessica M Lambert; Elizabeth F Lopez; Merry L Lindsey
Journal:  Int J Cardiol       Date:  2008-07-25       Impact factor: 4.164

10.  TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.

Authors:  A Amour; P M Slocombe; A Webster; M Butler; C G Knight; B J Smith; P E Stephens; C Shelley; M Hutton; V Knäuper; A J Docherty; G Murphy
Journal:  FEBS Lett       Date:  1998-09-11       Impact factor: 4.124

View more
  47 in total

1.  Incorporation of gold-coated microspheres into embryoid body of human embryonic stem cells for cardiomyogenic differentiation.

Authors:  Tae-Jin Lee; Seokyung Kang; Gun-Jae Jeong; Jeong-Kee Yoon; Suk Ho Bhang; Jaesur Oh; Byung-Soo Kim
Journal:  Tissue Eng Part A       Date:  2014-09-08       Impact factor: 3.845

2.  TGF-β1 and TIMP-4 regulate atrial fibrosis in atrial fibrillation secondary to rheumatic heart disease.

Authors:  Yu Sun; Zi-Yang Huang; Zhen-Hua Wang; Cui-Ping Li; Xian-Liang Meng; Yun-Jiao Zhang; Feng Su; Nan Ma
Journal:  Mol Cell Biochem       Date:  2015-05-14       Impact factor: 3.396

3.  Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.

Authors:  Vaibhav B Patel; Sreedhar Bodiga; Ratnadeep Basu; Subhash K Das; Wang Wang; Zuocheng Wang; Jennifer Lo; Maria B Grant; JiuChang Zhong; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circ Res       Date:  2012-04-03       Impact factor: 17.367

4.  Loss of Timp3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II.

Authors:  Ratnadeep Basu; Dong Fan; Vijay Kandalam; Jiwon Lee; Subhash K Das; Xiuhua Wang; Troy A Baldwin; Gavin Y Oudit; Zamaneh Kassiri
Journal:  J Biol Chem       Date:  2012-11-09       Impact factor: 5.157

5.  Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis.

Authors:  Hiroe Toba; Presley L Cannon; Andriy Yabluchanskiy; Rugmani Padmanabhan Iyer; Jeanine D'Armiento; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-23       Impact factor: 4.733

6.  Plasma levels of matrix metalloproteinase 9 in patients undergoing off-pump coronary artery bypass grafting.

Authors:  Haiqing Li; Zhize Yuan; Sen Li; Quan Qi; Jun Liu; Mi Zhou; Junfeng Cai; Anqing Chen; Zhe Wang; Xiaofeng Ye; Qiang Zhao
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

7.  Loss of TIMP3 selectively exacerbates diabetic nephropathy.

Authors:  Ratnadeep Basu; Jiwon Lee; Zuocheng Wang; Vaibhav B Patel; Dong Fan; Subhash K Das; George C Liu; Rohan John; James W Scholey; Gavin Y Oudit; Zamaneh Kassiri
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-15

8.  Matrix metalloproteinase inhibition influences aspects of photoperiod stimulated ovarian recrudescence in Siberian hamsters.

Authors:  Asha Shahed; Jamie J Simmons; Sydney L Featherstone; Kelly A Young
Journal:  Gen Comp Endocrinol       Date:  2015-04-21       Impact factor: 2.822

9.  Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK.

Authors:  Jalahalli M Siddesha; Anthony J Valente; Siva S V P Sakamuri; Tadashi Yoshida; Jason D Gardner; Naveen Somanna; Chiaki Takahashi; Makoto Noda; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2013-10-02       Impact factor: 5.000

10.  Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling.

Authors:  David C Lobb; Heather Doviak; Gregory L Brower; Eva Romito; Jason W O'Neill; Stephen Smith; James A Shuman; Parker D Freels; Kia N Zellars; Lisa A Freeburg; Aarif Y Khakoo; TaeWeon Lee; Francis G Spinale
Journal:  J Pharmacol Exp Ther       Date:  2020-09-21       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.